Caribou Biosciences vs Evommune
Evommune is the larger business, with $13.0m of revenue in fiscal 2025 against $11.2m for Caribou Biosciences (1.2 times as much). Evommune grew faster (85.7% against 11.7%). Evommune kept more of each dollar of sales as profit: a net margin of -529.8% against -1327.4%. Caribou Biosciences carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Caribou BiosciencesCRBU, 2025 | EvommuneEVMN, 2025 |
|---|---|---|
| Revenue | $11.2m | $13.0m |
| Revenue growth | 11.7% | 85.7% |
| Net income | −$148m | −$68.9m |
| Operating margin | -1329.4% | -623.6% |
| Net margin | -1327.4% | -529.8% |
| Return on equity | -79.0% | — |
| Free cash flow | −$112m | −$76.7m |
| Cash | $12.4m | $44.1m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 48 |
| Market value | $47.4m | $215m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 5 sales | 7 buys, 9 sales |